Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

16.70
+0.83005.23%
Volume:1.74M
Turnover:28.25M
Market Cap:1.98B
PE:-14.42
High:16.79
Open:16.03
Low:15.70
Close:15.87
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Cheesecake Factory, SiriusPoint, Arcutis Biosciences

Reuters
·
27 Feb

BUZZ-Arcutis Biotherapeutics rises on strong sales of skin disease drug

Reuters
·
26 Feb

Strong Buy Rating for Arcutis Biotherapeutics Driven by Zoryve’s Growth and Market Expansion

TIPRANKS
·
26 Feb

Arcutis Biotherapeutics Shares up 5.3% After Narrower Q4 Loss

THOMSON REUTERS
·
26 Feb

Arcutis Biotherapeutics Says FDA Accepts Supplemental New Drug Application for Zoryve Cream

MT Newswires Live
·
26 Feb

Arcutis Biotherapeutics Inc - FDA Sets Pdufa Target Action Date of Oct 13, 2025

THOMSON REUTERS
·
26 Feb

U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ Zoryve® (Roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis

THOMSON REUTERS
·
26 Feb

Arcutis Biotherapeutics Inc : Mizuho Raises Target Price to $21 From $20

THOMSON REUTERS
·
26 Feb

Arcutis Biotherapeutics Price Target Maintained With a $20.00/Share by Needham

Dow Jones
·
26 Feb

Stock Track | Arcutis Biotherapeutics (ARQT) Soars 9.18% Pre-Market on Stellar Q4 Results, Driven by Robust ZORYVE Sales

Stock Track
·
26 Feb

Arcutis Biotherapeutics Q4 Loss Narrows, Revenue Rises

MT Newswires Live
·
26 Feb

Arcutis Biotherapeutics Inc (ARQT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com
·
26 Feb

Arcutis Biotherapeutics Reports Strong 2024 Revenue Growth

TIPRANKS
·
26 Feb

Strong Market Position and Growth Potential for Arcutis Biotherapeutics Driven by Zoryve’s Success and Strategic Initiatives

TIPRANKS
·
26 Feb

Stock Track | Arcutis Biotherapeutics (ARQT) Soars 9% on Stellar Q4 Results Driven by ZORYVE Sales

Stock Track
·
26 Feb

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
26 Feb